Literature DB >> 21839132

DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Lara Vojnov1, Alexander T Bean, Eric J Peterson, Maria J Chiuchiolo, Jonah B Sacha, Ferencz S Denes, Matyas Sandor, Deborah H Fuller, James T Fuller, Christopher L Parks, Adrian B McDermott, Nancy A Wilson, David I Watkins.   

Abstract

The goals of a T cell-based vaccine for HIV are to reduce viral peak and setpoint and prevent transmission. While it has been relatively straightforward to induce CD8(+) T cell responses against immunodominant T cell epitopes, it has been more difficult to broaden the vaccine-induced CD8(+) T cell response against subdominant T cell epitopes. Additionally, vaccine regimens to induce CD4(+) T cell responses have been studied only in limited settings. In this study, we sought to elicit CD8(+) T cells against subdominant epitopes and CD4(+) T cells using various novel and well-established vaccine strategies. We vaccinated three Mamu-A*01(+) animals with five Mamu-A*01-restricted subdominant SIV-specific CD8(+) T cell epitopes. All three vaccinated animals made high frequency responses against the Mamu-A*01-restricted Env TL9 epitope with one animal making a low frequency CD8(+) T cell response against the Pol LV10 epitope. We also induced SIV-specific CD4(+) T cells against several MHC class II DRBw*606-restricted epitopes. Electroporated DNA with pIL-12 followed by a rAd5 boost was the most immunogenic vaccine strategy. We induced responses against all three Mamu-DRB*w606-restricted CD4 epitopes in the vaccine after the DNA prime. Ad5 vaccination further boosted these responses. Although we successfully elicited several robust epitope-specific CD4(+) T cell responses, vaccination with subdominant MHC class I epitopes elicited few detectable CD8(+) T cell responses. Broadening the CD8(+) T cell response against subdominant MHC class I epitopes was, therefore, more difficult than we initially anticipated.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21839132      PMCID: PMC3186839          DOI: 10.1016/j.vaccine.2011.07.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  66 in total

1.  Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses.

Authors:  W Chen; L C Antón; J R Bennink; J W Yewdell
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

Review 2.  Helping the CD8(+) T-cell response.

Authors:  Michael J Bevan
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

3.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

4.  Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice.

Authors:  Theodora Fifis; Patricia Mottram; Violeta Bogdanoska; Jennifer Hanley; Magdalena Plebanski
Journal:  Vaccine       Date:  2004-11-25       Impact factor: 3.641

5.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.

Authors:  Bianca R Mothé; Helen Horton; Donald K Carter; Todd M Allen; Max E Liebl; Pam Skinner; Thorsten U Vogel; Sarah Fuenger; Kathy Vielhuber; William Rehrauer; Nancy Wilson; Genoveffa Franchini; John D Altman; Ashley Haase; Louis J Picker; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA.

Authors:  T M Pertmer; M D Eisenbraun; D McCabe; S K Prayaga; D H Fuller; J R Haynes
Journal:  Vaccine       Date:  1995       Impact factor: 3.641

8.  Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.

Authors:  Rong Xu; Shakuntala Megati; Vidia Roopchand; Amara Luckay; Amjed Masood; Dorys Garcia-Hand; Margherita Rosati; David B Weiner; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; John H Eldridge; Michael A Egan
Journal:  Vaccine       Date:  2008-07-25       Impact factor: 4.169

9.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

10.  Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes.

Authors:  Bianca Obermaier; Marc Dauer; Jan Herten; Katharina Schad; Stefan Endres; Andreas Eigler
Journal:  Biol Proced Online       Date:  2003-10-24       Impact factor: 3.244

View more
  6 in total

1.  IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques.

Authors:  Rashmi Jalah; Vainav Patel; Viraj Kulkarni; Margherita Rosati; Candido Alicea; Brunda Ganneru; Agneta von Gegerfelt; Wensheng Huang; Yongjun Guan; Kate E Broderick; Niranjan Y Sardesai; Celia LaBranche; David C Montefiori; George N Pavlakis; Barbara K Felber
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

2.  Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239.

Authors:  Mauricio A Martins; Nancy A Wilson; Shari M Piaskowski; Kim L Weisgrau; Jessica R Furlott; Myrna C Bonaldo; Marlon G Veloso de Santana; Richard A Rudersdorf; Eva G Rakasz; Karen D Keating; Maria J Chiuchiolo; Michael Piatak; David B Allison; Christopher L Parks; Ricardo Galler; Jeffrey D Lifson; David I Watkins
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

3.  Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates.

Authors:  Hadar Marcus; Emily Thompson; Yan Zhou; Michael Bailey; Mitzi M Donaldson; Daphne A Stanley; Clement Asiedu; Kathryn E Foulds; Mario Roederer; Juan I Moliva; Nancy J Sullivan
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

4.  Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.

Authors:  José R Vasconcelos; Mariana R Dominguez; Adriano F Araújo; Jonatan Ersching; Cibele A Tararam; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Front Immunol       Date:  2012-12-04       Impact factor: 7.561

5.  HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.

Authors:  Saravana Kanagavelu; James M Termini; Sachin Gupta; Francesca N Raffa; Katherine A Fuller; Yaelis Rivas; Sakhi Philip; Richard S Kornbluth; Geoffrey W Stone
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

6.  Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques.

Authors:  Viraj Kulkarni; Antonio Valentin; Margherita Rosati; Candido Alicea; Ashish K Singh; Rashmi Jalah; Kate E Broderick; Niranjan Y Sardesai; Sylvie Le Gall; Beatriz Mothe; Christian Brander; Morgane Rolland; James I Mullins; George N Pavlakis; Barbara K Felber
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.